Free Trial

Orgenesis (ORGS) Competitors

Orgenesis logo
$1.04 -0.07 (-6.31%)
As of 03:59 PM Eastern

ORGS vs. JATT, ELEV, CMMB, LGVN, CLDI, NAII, RLMD, RVPH, FNCH, and VYNE

Should you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include JATT Acquisition (JATT), Elevation Oncology (ELEV), Chemomab Therapeutics (CMMB), Longeveron (LGVN), Calidi Biotherapeutics (CLDI), Natural Alternatives International (NAII), Relmada Therapeutics (RLMD), Reviva Pharmaceuticals (RVPH), Finch Therapeutics Group (FNCH), and VYNE Therapeutics (VYNE). These companies are all part of the "pharmaceutical products" industry.

Orgenesis vs. Its Competitors

JATT Acquisition (NYSE:JATT) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by insiders. Comparatively, 5.7% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, JATT Acquisition's average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company Overall Sentiment
JATT Acquisition Neutral
Orgenesis Neutral

JATT Acquisition has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat JATT Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
JATT AcquisitionN/A -49.58% 2.84%
Orgenesis -3,827.81%N/A -130.18%

JATT Acquisition has higher earnings, but lower revenue than Orgenesis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
JATT AcquisitionN/AN/A$6.85MN/AN/A
Orgenesis$662K7.54-$55.36MN/AN/A

Summary

JATT Acquisition beats Orgenesis on 5 of the 7 factors compared between the two stocks.

Get Orgenesis News Delivered to You Automatically

Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ORGS vs. The Competition

MetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$4.99M$816.22M$5.54B$9.41B
Dividend YieldN/A4.84%3.75%4.03%
P/E RatioN/A1.2021.0120.09
Price / Sales7.5425.49433.8199.01
Price / CashN/A19.5636.1658.27
Price / Book-0.166.878.125.65
Net Income-$55.36M-$4.17M$3.25B$257.91M
7 Day Performance-2.80%0.03%0.97%2.09%
1 Month Performance-36.97%2.12%7.36%11.13%
1 Year PerformanceN/A2.14%31.31%18.40%

Orgenesis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ORGS
Orgenesis
N/A$1.04
-6.3%
N/AN/A$4.99M$662K0.00150Gap Down
JATT
JATT Acquisition
N/A$1.31
-5.8%
N/A-62.9%$22.60MN/A0.003High Trading Volume
ELEV
Elevation Oncology
2.7645 of 5 stars
$0.38
+0.8%
$3.39
+791.0%
-87.0%$22.51MN/A-0.4640
CMMB
Chemomab Therapeutics
2.8243 of 5 stars
$1.17
+1.2%
$8.50
+626.5%
-3.4%$22.06MN/A-1.5420Gap Up
LGVN
Longeveron
3.3685 of 5 stars
$1.42
flat
$8.67
+510.3%
-60.5%$21.20M$2.23M-0.2320Positive News
Gap Up
CLDI
Calidi Biotherapeutics
0.4785 of 5 stars
$0.58
-23.8%
N/A-65.4%$21.03MN/A0.0038Gap Down
NAII
Natural Alternatives International
1.3108 of 5 stars
$3.40
-2.6%
N/A-42.1%$21.01M$125.48M-2.45290Positive News
Gap Down
RLMD
Relmada Therapeutics
4.7501 of 5 stars
$0.63
+2.9%
$5.00
+696.8%
-84.0%$20.83MN/A-0.2510
RVPH
Reviva Pharmaceuticals
3.3882 of 5 stars
$0.43
+9.7%
$9.00
+1,996.4%
-66.1%$20.61MN/A-0.545Positive News
Gap Up
High Trading Volume
FNCH
Finch Therapeutics Group
0.7891 of 5 stars
$12.75
flat
N/A+756.2%$20.48MN/A-1.45190
VYNE
VYNE Therapeutics
2.9445 of 5 stars
$1.33
-6.3%
$6.25
+369.9%
-46.7%$20.23M$500K-1.3430Positive News
High Trading Volume

Related Companies and Tools


This page (NASDAQ:ORGS) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners